International SDH Consortium
During the past three years, mutations have been identified in SDHB and SDHD (genes encoding for SDHB and SDHD, component peptides of mitochondrial complex II) in patients with familial pheochromocytoma and apparently sporadic pheochromocytoma.

As these tumors are rare, there is a paucity of information with regard to genotype/phenotype correlations and penetrance of disease in families with identified SDHB and SDHD mutations.

In an effort to answer these questions, we have established an International SDH Consortium and are seeking international cooperation to achieve sufficient numbers to draw statistically relevant conclusions. We currently have 60 families entered and would welcome the inclusion of any patients/families in whom germline SDHB or SDHD mutations have been identified in association with pheochromocytoma and /or paraganglioma. It is intended that the results of the study be submitted for publication in a peer- reviewed journal.

The study involves patient consent for the clinician to complete a Data Information sheet on the patientÕs medical history and then the de-identified data to be sent to the co-ordinating centre. Family members who have been identified as SDHB or SDHD mutation positive, but who do not have evidence of disease are also invited to participate.

For more information please contact: Dr Dindy Benn at dbenn@med.usyd.edu.au

International SDH Consortium Coordinating Group
Cancer Genetics
Kolling Institute of Medical Research
Royal North Shore Hospital
St Leonards, NSW 2065, Australia

Professor Bruce Robinson MD MSc FRACP at bgr@med.usyd.edu.au
Dr Deborah Marsh BScAgr PhD at dmarsh@med.usyd.edu.au
Dr Dindy Benn MSc (Med) PhD at dbenn@med.usyd.edu.au
Ms Jennifer Reilly B Comm at jreilly@gmp.usyd.edu.au

Visit Royal North Shore's Website.